MedicinemedRxiv
Ranked by formulaVerdict: NotableIndividual Angiotensin Receptor Blockers and Risk of Dementia: A Target Trial Emulation Study
Observational studies suggest that angiotensin receptor blockers (ARBs) are associated with lower dementia risk than angiotensin-converting enzyme inhibitors (ACEIs).
Key numbers
- 95% CIs
Caveats
- Preprint; not yet peer reviewed.
VerdictWorth a reader's time today.
Abstract
INTRODUCTION: Observational studies suggest that angiotensin receptor blockers (ARBs) are associated with lower dementia risk than angiotensin-converting enzyme inhibitors (ACEIs). Whether dementia risk differs across individual ARBs remains uncertain and was investigated in this study. METHODS: This retrospective cohort study emulated target trials using electronic health record and claims data from 44 US health care organizations in the TriNetX Linked Research Network. ACEI/ARB-naive adults aged 55 to 80 years initiating an ARB or lisinopril were eligible. Separate 1:1 propensity-score matching was performed for each comparison. Individual and pooled ARBs were compared with lisinopril (between-class), and non-losartan ARBs with losartan (within-class). The primary outcome was incident all-cause dementia; secondary outcomes included Alzheimer disease, vascular dementia, cerebral infarction, death, and dementia or death. Cox models estimated hazard ratios (HRs) and 95% CIs. Sensitivity analyses included lagged and treatment-persistence analyses, control outcomes, and E-values. RESULTS: Of 22,025,599 individuals screened, 2,051,275 were eligible; matched cohorts ranged from 10,113 to 857,773, with median follow-up of 4.7 to 7.2 years. Pooled ARBs were associated with lower dementia risk than lisinopril (HR, 0.86; 95% CI, 0.85 to 0.87), with substantial variation across individual agents (HR range, 0.66 to 0.93). Within-class comparisons showed similar heterogeneity (HR range, 0.68 to 0.94) and reproduced between-class agent ordering by HR estimates. Considerable agent-level variation was also observed across secondary outcomes. Losartan, the most commonly prescribed ARB, had the least favorable dementia associations. Negative-control associations were near null within class, and sensitivity analyses supported robustness. DISCUSSION: Individual ARBs were associated with differing dementia risks, suggesting clinically relevant within-class heterogeneity pending confirmation in randomized trials.
The editor's rubric
| Dimension | Level | Weight | What that level means |
|---|---|---|---|
| Leverage | ██░░░ 2 | 10% | Reusable within one subfield (a technique, dataset, or protocol a few groups will adopt). |
| Magnitude | ██░░░ 2 | 20% | Solid incremental gain on a meaningful problem. |
| Evidence | ████░ 4 | 32% | Strong: large scale, preregistered, independently replicated, or a well-powered randomized trial. |
| Novelty | ██░░░ 2 | 8% | A new combination of known ideas. |
| Trajectory | ██░░░ 2 | 5% | Some room to improve with obvious engineering. |
| Stakes | ███░░ 3 | 25% | Meaningful benefit to many people within a few years. |
Editor’s rationale
Heuristic triage from title and abstract text only, not a reading of the paper. Cues found: novelty (open problem); design (randomized); verification (confidence interval, independent replication); stakes (mortality, major disease, prevention or cure). Red flags: weak evidence (single site).
How the score was computed
- Merit
- 5.8 / 10
- Adjusted merit
- 4.8 / 10
- Attention
- 0%
- Freshness
- 92%